Win Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB)

Win Advisors Inc. bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, HoldingsChannel.com reports. The firm bought 6,686 shares of the biotechnology company’s stock, valued at approximately $1,022,000.

Other institutional investors have also made changes to their positions in the company. Retirement Systems of Alabama lifted its holdings in Biogen by 491.9% during the 4th quarter. Retirement Systems of Alabama now owns 185,383 shares of the biotechnology company’s stock valued at $28,349,000 after purchasing an additional 154,062 shares during the last quarter. Old North State Wealth Management LLC lifted its holdings in Biogen by 14.3% during the 4th quarter. Old North State Wealth Management LLC now owns 15,467 shares of the biotechnology company’s stock valued at $2,365,000 after purchasing an additional 1,934 shares during the last quarter. ARGA Investment Management LP lifted its holdings in Biogen by 34.7% during the 4th quarter. ARGA Investment Management LP now owns 3,532 shares of the biotechnology company’s stock valued at $540,000 after purchasing an additional 910 shares during the last quarter. E. Ohman J or Asset Management AB lifted its holdings in Biogen by 14.3% during the 4th quarter. E. Ohman J or Asset Management AB now owns 6,399 shares of the biotechnology company’s stock valued at $979,000 after purchasing an additional 800 shares during the last quarter. Finally, Mather Group LLC. lifted its holdings in Biogen by 476.0% during the 4th quarter. Mather Group LLC. now owns 1,728 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 1,428 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BIIB. Wolfe Research began coverage on shares of Biogen in a report on Friday, November 15th. They set a “peer perform” rating for the company. William Blair reissued an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Wells Fargo & Company dropped their target price on shares of Biogen from $190.00 to $165.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. TD Cowen dropped their target price on shares of Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Finally, Oppenheimer dropped their target price on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Sixteen investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $228.80.

Biogen Stock Up 0.1 %

Biogen stock opened at $142.49 on Wednesday. The stock has a market capitalization of $20.76 billion, a PE ratio of 12.87, a price-to-earnings-growth ratio of 1.66 and a beta of -0.08. Biogen Inc. has a twelve month low of $139.71 and a twelve month high of $246.44. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average of $150.47 and a 200-day moving average of $177.77.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.